Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.

This was a dose-ranging, placebo-controlled study

The 2023 phase 2 obesity trial randomly assigned 338 adults with obesity, or overweight plus a weight-related condition, to several once-weekly retatrutide dose-escalation regimens or placebo. It was double-blind and followed participants for 48 weeks; the prespecified primary endpoint was percentage change in body weight at week 24.

The publication also reported week-48 body-weight change, categorical weight-change thresholds and safety observations. Separating the primary endpoint from later and secondary outcomes prevents a headline result from obscuring what was planned in advance.

Evidence should become more specific as a claim becomes more consequential.

Report the result with its comparator and adverse events

At week 24, the published least-squares mean percentage changes in body weight differed across dose groups and placebo; at week 48, the reported changes also varied by dose. Those values describe the trial intervention and titration schedules, not a general property of a compound name.

The paper reported gastrointestinal adverse events as the most common events in retatrutide groups and described dose-related increases in heart rate that peaked at week 24 and declined thereafter. Safety reporting belongs alongside efficacy reporting, not in a separate footnote.

The EternaGen reporting standard
  • Link to the original source.
  • Name the study design and population.
  • Report the observed endpoint factually.
  • Disclose important limitations.
  • Never convert trial reporting into a product recommendation.

Phase 2 evidence is not the end of the question

The study was limited to 48 weeks, its eligibility criteria define the population, and its results were generated under a controlled protocol. Trial findings do not verify identity, purity, dosing or safety of any non-trial material.

The publication lists Eli Lilly funding and investigator affiliations. Sponsorship does not invalidate a study, but it is context a careful reader should retain when weighing evidence. This educational record makes no treatment recommendation or personal-use claim.

Primary references

These sources were checked against the linked publisher, regulator or literature-index record on 21 July 2026.

  1. Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
  2. Rosenstock et al. Retatrutide for people with type 2 diabetes: randomized phase 2 trial. Lancet. 2023. PMID 37385280.
  3. Sanyal et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial. Lancet. 2024. PMID 38858523.
Educational content only. This article does not constitute medical advice, a therapeutic claim or a recommendation for human or veterinary use.